Skip to content
Search

Latest Stories

More than 50,000 pregnant women got first dose of Covid-19 vaccine in England

A total of 51,724 pregnant women in England have received their first dose of Covid-19 vaccine, the data from Public Health England (PHE) revealed, as the agency has encouraged more pregnant women to come forward for the vaccination. 

The data shows that these were all women aged under 50 years of age, who reported that they were pregnant or could be pregnant at the time of receiving the vaccine. Of these, 20,648 women have received their second dose.


On 16 April 2021, the Joint Committee on Vaccination and Immunisation (JCVI) advised that pregnant women should be offered the Covid-19 vaccine at the same time as the rest of the population, based on their age and clinical risk group.

Some pregnant women will have been vaccinated before this date if they are clinically vulnerable or are a healthcare worker, therefore these figures are likely to be much higher.

It is preferable for pregnant women in the UK to be offered the Pfizer-BioNTech or Moderna vaccines where available, as there is more safety data available on these vaccines in pregnancy.

Vaccines Minister Nadhim Zahawi said: "It is brilliant to see so many pregnant women coming forward for their Covid-19 vaccines, ensuring they protect themselves and their baby from this awful virus.

"While uncommon, severe illness from Covid-19 is more likely in later pregnancy and infection increases the risk of a premature birth. The Covid-19 vaccines are one of the best defences against infection, preventing at least 11.7 million infections in England alone. I urge everyone – including pregnant women – to get their vaccines as soon as they can."

The Pfizer-BioNTech and Moderna vaccines are recommended for pregnant women in the UK because these vaccines have been given to over 130,000 pregnant women in the US and the data has not raised any safety concerns.

Women who are planning pregnancy, who are in the immediate postpartum period, or who are breastfeeding can be vaccinated with any vaccine, depending on their age and clinical risk group.

New data from PHE has also showed that the vaccination programme has directly averted over 52,600 hospitalisations (approximately 8,800 admissions in those aged 65 to 74; 20,300 in those aged 75 to 84; and 23,500 in those aged 85 and over).

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less